For decades, the dopamine D1 receptor (D1R) is thought to be the therapeutic target for Parkinson’s disease, attention deficit hyperactivity disorder and cognitive impairment in schizophrenia, where normal D1R signaling is impaired1–5. Here, DRD1 is linked to attention deficit-hyperactivity disorder.